Nuvectis Pharma (NVCT) AI Stock Analysis

• Market Cap: $215.64M
• Dividend Yield: N/A
• Average Volume (3M): 89.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.74
• Revenue Growth: N/A
• EPS Growth: -16.26%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 26,491,701
• 10 Day Avg. Volume: 112,705
• 30 Day Avg. Volume: 89,483
• PEG Ratio: -0.33
• Price to Book (P/B): 8.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.29
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -6.69
• 1Y Price Target: $13.50
• Price Target Upside: 65.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.24
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $7.50 ▼(-7.86% Downside)
• Action: Reiterated Date: 02/12/26
• Date: Action: Reiterated 02/12/26

The score is held back primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn implying continued external funding risk). Technicals are a meaningful positive with price above key moving averages and positive momentum, but valuation remains constrained by negative earnings and no stated dividend yield.

Positive Factors

Conservative balance sheet (no debt)

Zero reported debt materially reduces insolvency and interest burden risk for a clinical‑stage biopharma. This durable capital structure gives management more optionality to prioritize development milestones or seek strategic partnerships without immediate debt servicing constraints.

Negative Factors

No revenue stream

Absence of product revenue across multiple years leaves the company wholly dependent on external financing or deals to fund operations. Without revenue, there's no internal cash cushion to support development, increasing dilution and strategic vulnerability until commercialization.

Nuvectis Pharma Business Overview & Revenue Model

Company Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment...

Read more

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment...

How the Company Makes Money

As a clinical-stage biotechnology company, Nuvectis Pharma does not have publicly available information indicating recurring revenue from approved product sales. Its funding and cash inflows are therefore primarily associated with capital-raising ...

Read more

As a clinical-stage biotechnology company, Nuvectis Pharma does not have publicly available information indicating recurring revenue from approved product sales. Its funding and cash inflows are therefore primarily associated with capital-raising ...

Nuvectis Pharma Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-27.57M	-19.00M	-22.90M	-19.23M	-12.89M
Net Income	-26.44M	-19.00M	-22.26M	-19.09M	-12.89M
Balance Sheet
Total Assets	31.71M	18.61M	19.18M	20.41M	6.66M
Cash, Cash Equivalents and Short-Term Investments	31.63M	18.53M	19.13M	19.99M	5.74M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	13.30M	8.89M	6.98M	6.19M	17.66M
Stockholders Equity	18.41M	9.71M	12.20M	14.22M	-11.01M
Cash Flow
Free Cash Flow	-16.01M	-12.25M	-15.95M	-13.56M	-9.50M
Operating Cash Flow	-16.01M	-12.25M	-15.95M	-13.56M	-9.50M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	29.11M	11.65M	15.09M	27.81M	15.25M

Nuvectis Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.14
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCT, the sentiment is Positive. The current price of 8.14 is below the 20-day moving average (MA) of 8.16, below the 50-day MA of 8.51, and above the 200-day MA of 7.32, indicating a neutral trend. The MACD of -0.25 indicates Negative momentum. The RSI at 49.27 is Neutral, neither overbought nor oversold. The STOCH value of 59.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVCT.

Nuvectis Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVCT	52 Neutral	$215.64M	-6.23	-131.80%	―	―	-16.26%
OBIO	52 Neutral	$249.88M	-3,008.78	-169.64%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PYXS	46 Neutral	$92.36M	-0.90	-87.28%	―	-82.53%	-52.00%
NKTX	44 Neutral	$164.68M	-1.32	-30.02%	―	―	25.84%
MOLN	43 Neutral	$170.39M	-2.09	-49.86%	―	-100.00%	11.02%